A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

Shares of Novavax Inc. NVAX slid 4.44% to $7.11 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.27% to ...

Shares of Novavax Inc. NVAX shed 5.06% to $7.51 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 2.04% to 23,348.64 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

The FDA has issued a long-awaited approval of Novavax's COVID-19 vaccine (Nuvaxovid), but with unusual restrictions. Novavax makes the nation's only traditional protein-based coronavirus vaccine -- ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax ( (NVAX)) has issued an update.

A Truth Social post shared by President Donald Trump on Sept. 26 provided multiple pieces of vaccine advice that do not align with his administration’s recent recommendations, potentially creating ...

The FDA recently approved new COVID-19 vaccines for Americans, but due to certain restrictions, there has been mounting confusion on what they are, how much protection they’ll offer and whether ...

The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at ...

The Food and Drug Administration on Wednesday authorized updated COVID-19 vaccines, but limited their use for most age groups and rescinded the emergency use authorization that made shots available ...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...